TableĀ 1

Pertinent findings of molecular profiling of the recurrent tumour performed by Caris Moleculare Intelligence (CARIS)

TestMethodResult
BRCA 1NGSExon 3/E33K; mutated variant of unknown significance
BRCA2NGSExon 17/A263v; mutated variant of unknown significance
ERCC1IHCNegative
IDH1NGSMutated Exon 4/R132H
MGMTPyro SeqMethylated
1p19qFISHPositive
FGFR1NGSMutated, variant of unknown significance; Exon 4 E126K
FGFR2NGSMutation negative
PD-L1IHCNegative
TP53NGSMutated; Exon 8/P2785
EGFRNGSMutation negative
EGFR vIIIFAAbsent
NRAS/KRAS/HRASNGSMutation negative
Her2/Neu (ERBB2)NGSMutation negative
PIK3CANGSMutation negative
  • EGFR, epithelial growth factor receptor; EGFR, epithelial growth factor receptor; ERBB, epidermal growth factor receptor; ERCC, excision repair cross-complementing; FGFR, fibroblast growth factor receptor; FA, Fragment Analysis ; FISH, fluorescence in situ hybridization; IDH, isocitrate dehydrogenase; IHC, Immunohistochemistry; MGMT, O6 methylguanine-DNA methyltransferase; NGS, Next-Generation sequencing; NRAS/KRAS/HRAS, N-rat sarcoma gene; K-rat sarcoma gene; H-rat sarcoma gene; PD-L1, programmed death ligand 1; PIK3CA, Phosphoinositide 3-kinase oncogene; TP53, tumor protein 53.